Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug:519:267-275.
doi: 10.1016/j.cca.2021.05.011. Epub 2021 May 17.

The PrecivityAD™ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis

Kristopher M Kirmess  1 , Matthew R Meyer  2 , Mary S Holubasch  2 , Stephanie S Knapik  2 , Yan Hu  2 , Erin N Jackson  2 , Scott E Harpstrite  2 , Philip B Verghese  2 , Tim West  2 , Ilana Fogelman  2 , Joel B Braunstein  2 , Kevin E Yarasheski  2 , John H Contois  2
Affiliations

The PrecivityAD™ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis

Kristopher M Kirmess et al. Clin Chim Acta. 2021 Aug.

Abstract

Background: There is an unmet need for an accessible, less invasive, cost-effective method to facilitate clinical trial enrollment and aid in clinical Alzheimer's disease (AD) diagnosis. APOE genotype affects the clearance and deposition of amyloid-beta (Aβ) with APOE4 carriers having increased risk while APOE2 alleles appear to be protective. Lower plasma Aβ42/40 correlates with brain amyloidosis. In response, C2N has developed the PrecivityAD™ test; plasma LC-MS/MS assays for Aβ isoform quantitation and qualitative APOE isoform-specific proteotyping.

Methods: In accord with CLIA standards, we developed and validated assay performance: precision, accuracy, linearity, limit of detection (LoD), interferences.

Results: Within-day precision varied from 1.5-3.0% (Aβ40) and 2.5-8.4% (Aβ42). Total (within-lab) variability was 2.7-7.7% (Aβ40) and 3.1-9.5% (Aβ42). Aβ40 quantitation was linear from 10 to 1780 pg/mL; Aβ42 was linear from 2 to 254 pg/mL. LoD was 11 and 2 pg/mL for Aβ40 and Aβ42, respectively. APOE proteotypes were 100% concordant with genotype, while LoD (fM) was much lower than APOE concentrations observed in plasma (mM).

Conclusions: The PrecivityAD™ assays are precise, accurate, sensitive, and linear over a wide analytical range, free from significant interferences, and suitable for use in the clinical laboratory.

Keywords: Alzheimer’s disease; Apolipoprotein E; Aβ 42/40; Beta-amyloid; Biomarkers.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Aβ40 and Aβ42 Linearity
See this image and copyright information in PMC

References

    1. Aisen P, Touchon J, Andrieu S, Boada M, Doody R, Nosheny RL, et al. Registries and Cohorts to Accelerate Early Phase Alzheimer’s Trials. A Report from the E.U./U.S. Clinical Trials in Alzheimer’s Disease Task Force. J Prev Alzheimer’s Dis 2016;3:68–74. - PubMed
    1. Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 2016;87:539–47. - PMC - PubMed
    1. Corder EH, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993; 261:921–3. - PubMed
    1. Liu CC1, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013; 9:106–18. - PMC - PubMed
    1. Verghese PB, Castellano JM, and Holtzman DM, Roles of Apolipoprotein E in Alzheimer’s Disease and Other Neurological Disorders. Lancet Neurol 2011; 10: 241–252. - PMC - PubMed